The Genetic and Scientific Basis, Molecular Biology, and Mechanistic Rationale for Lowering LDL Through PCSK9 and APOB Inhibition and Other Novel Targets: Translating Genetic and Epidemiologic Evidence to the Front Lines of Diabetes Care - Michael H. Davidson, MD, FACC, FACP, FNLA

The Genetic and Scientific Basis, Molecular Biology, and Mechanistic Rationale for Lowering LDL Through PCSK9 and APOB Inhibition and Other Novel Targets: Translating Genetic and Epidemiologic Evidence to the Front Lines of Diabetes Care - Michael H. Davidson, MD, FACC, FACP, FNLA

Published

June 16, 2015

Created by

CMEducation Resources symposium